Chugai Seiyaku Kabushiki Kaisha

F. Hoffmann-La Roche Ag

The University of Tokyo

Hirosato Ebiike

Hiroki Nishii

Yoshito Nakanishi

Lisha Wang

Nobuo Shimma

Hidenori Takahashi

Yasuhiro Tamaki

Masami Kochi

Jun Ohwada

Tadakatsu Hayase

Masayuki Matsushita

Kenji Morikami

Nobuya Ishii

Masayuki Ohmori

WeiLi Zhao

Naoki Taka

Ikumi Hyodo

Toshiyuki Mio

Kyoko Takami

Nobuhiro Oikawa

Eisaku Mizuguchi

Satoshi Niizuma

Fumio Watanabe

Toshiyuki Tsukaguchi

Hatsuo Kawada

Sawako Ozawa

Toshihiro Aoki

Mitsuaki Nakamura

Masami Hasegawa

Kohei Koyama

Kimitaka Nakama

Miyuki Yoshida

Shun Yamamoto

Hiroyuki Shimamura

Aiko Suge

Takashi Chiba

Natsuki Kobayashi

Weili Zhao

An objective of the present invention is to provide low-molecular-weight compounds that can inhibit Src family kinases. The present invention relates to compounds represented by general formula (I) or pharmacologically acceptable salts thereof. In the formula, Aris optionally substituted Carylene or 5- to 10-membered heteroarylene, and Aris optionally substituted Caryl or 5- to 10-membered heteroaryl. Rand Rare defined as described in the specification.

Aminopyrazole derivatives

A method for treating cancer that includes administering a pharmaceutically effective amount of a composition containing a compound represented by formula (I) or a pharmacologically acceptable salt thereof. In the formula, A represents a 5- to 10-membered heteroaryl group, or a Caryl group; Rand Rindependently represent H, OH, X, CN, NO, a Chaloalkyl group, a Calkyl group, or the like &#x3c;Rand Rtogether form a (substituted) 3- to 10-membered heterocyclyl group or a (substituted) 5- to 10-membered heteroaryl group&#x3e;; Rrepresents H, a Calkyl group, a Caryl group, a Calkyl group, or a Chaloalkyl group; and Rrepresents H, X, a Calkyl group, a Chaloalkyl group, OH, CN, NO, or the like. 

Aminopyrazole derivative

A compound represented by formula (I) or a pharmacologically acceptable salt thereof, which can inhibit a fibroblast growth factor receptor (FGFR) family kinase in cancer tissues. (In the formula, A represents a 5- to 10-membered heteroaryl group, or a Caryl group; Rand Rindependently represent H, OH, X, CN, NO, a Chaloalkyl group, a Calkyl group, or the like &#x3c;Rand Rtogether form a (substituted) 3- to 10-membered heterocyclyl group or a (substituted) 5- to 10-membered heteroaryl group&#x3e;; Rrepresents H, a Calkyl group, a Caryl group, a Calkyl group, or a Chaloalkyl group; and Rrepresents H, X, a Calkyl group, a Chaloalkyl group, OH, CN, NO, or the like.) 

It is intended to provide a compound represented by the formula (1): [wherein Ar is an arylene group to be attached selected from the following formula (2): (wherein * represents a binding site to a nitrogen atom and ** represents a binding site to T); T represents &#x2014;(O)&#x2014;R; R represents a C-Calkyl group or the like; n represents 0 or 1; X represents O or the like; R, Rand Rare independently selected from a hydrogen atom or C-Calkyl; or Rand Rmay join together with an urea structure containing the nitrogen atoms to which they bind to form a 5- or 6-membered heterocycle; Y represents CH or N], or a pharmaceutically acceptable salt thereof or a prodrug thereof and a pharmaceutical composition containing the same.

Pyrazolopyridine and pyrrolopyridine multikinase inhibitors

A drug is provided that is useful as a preventive or therapeutic for cancer as a result of having superior PI3K inhibitory effects as well as superior stability in the body and water-solubility. A compound, or pharmaceutically acceptable salt thereof, represented by formula (I): [wherein, X represents a single bond, etc.; Y represents a single bond, etc. (provided that X and Y are not simultaneously single bonds); Z represents a hydrogen atom, etc.; m represents an integer of 1 or 2; and Rrepresents a cyclic substituent].

Pyrimidine derivatives as PI3K inhibitor and use thereof

Growing community of inventors

Kanagawa, Japan

Hirosato Ebiike